Business
Oxford Biomedica Appoints Frank Mathias as CEO
Oxford Biomedica Appoints Frank Mathias as CEO.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n \n \n \n \n \n Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer\n \n \n \n Oxford, UK - 22 November 2022: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Company\"), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.\n \n Dr Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica. Since 2016 he has served as CEO of Rentschler Biopharma SE (\"Rentschler\"), which he has successfully developed into a leading global, full-service CDMO. During the past six years, Dr Mathias has overseen a tripling of revenues, transformed the business, increased efficiencies and enhanced profitability even faster than revenues. At Rentschler, he also led the acquisition and rapid integration of a new site from Shire in Milford near Boston, US, and the establishment of a new gene therapies unit in Stevenage, UK. During his tenure, Rentschler was also the first CDMO in Europe to support the commercial production of the mRNA vaccine for BioNTech and also successfully transferred the commercial production process for Curevac's mRNA vaccine.\n \n Prior to Rentschler, Dr Mathias was CEO of publicly listed Medigene AG, an immuno-oncology company focusing on the development of T-cell-based cancer therapies. Over the course of his 30-year career, Dr Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen, Servier and Hoechst AG. In 2019 he was awarded the title of \"EY Entrepreneur of the Year\" in Germany.\n \n Dr Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March 2023, at which point Dr Mathias will fully take over the role of CEO and Dr Doliveux will resume the role of Non-Executive Chair.\n \n \n \n \n \n C...